Thus, SiHa cells were treated with GeXIVA or TxID, and CaSki cells were treated with GeXIVA to evaluate their inhibition effects, which may make further explanation of the role of these highly expressed α3, α9, α10, and β4 nAChR subunits in cervical cancer and indicate the putative treatment of α*-conotoxins on cervical cancer due to their high selectivities to α9α10 nAChR and α3β4 nAChR. The gene discussed is CHRNA4; the disease is cervical carcinoma.